ArticleScientific reports2025
Toxoplasma GRA16 attenuates Tau hyperphosphorylation and enhances autophagy in thrombin-treated HT-22 hippocampal neuronal cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Attenuation of Tau Hyperphosphorylation by Chronic Toxoplasma gondii Infection in a Mouse Model of Alzheimer's Disease.Parasite immunology · 2026Article
- Study on the Effects and Mechanisms of Resveratrol in Improving Cognitive Impairment in AβJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- FOXO family and neurodegenerative diseases: Mechanisms of action and therapeutic potential.Redox biology · 2026Review
- Crosstalk Between Allergic Inflammation and Autophagy.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study investigated whether Toxoplasma gondii-derived dense granule protein 16 (GRA16) modulates tau protein to attenuate tau hyperphosphorylation and promotes autophagy to facilitate the removal of tau aggregates. HT-22 murine hippocampal neuronal cells were treated with thrombin to induce rapid hyperphosphorylations and tau aggregation. Thrombin increased hyperphosphorylated tau protein levels and activated NF-κB, contributing to tau pathology and neuroinflammation. NF-κB activation increased apolipoprotein E (APOE) expression and decreased forkhead box O3A (FOXO3A) expression, a factor involved in autophagy regulation, consequently limiting the expression of autophagy-related genes directly regulated by FOXO3A. Meanwhile, in GRA16-transfected HT-22 cells treated with thrombin, GRA16 upregulated proteins involved in tau dephosphorylation but downregulated protein involved in tau phosphorylation. Moreover, GRA16 inhibited thrombin-induced NF-κB activation and increased FOXO3A levels, thereby enhancing the expression of autophagy-related genes, including those directly regulated by FOXO3A. GRA16 enhanced intracellular autophagic flux and inhibited tau hyperphosphorylations in thrombin-treated HT-22 cells, as evidenced by increased autophagic fluorescence and significant reductions in phosphorylated tau protein levels and fluorescence intensity. These findings suggest that GRA16 possesses therapeutic potential in tauopathies by enhancing tau dephosphorylation and autophagy-mediated tau clearance, establishing a conceptual foundation for developing new therapeutic approaches targeting tau pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.